Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pivotal Data Put Roche's Kadcyla In Position For Earlier Breast Cancer

Oct 16 2018

• By Emily Hayes

Digital illustration of Cancer cell in colour background

Related Content

Beyond <em>Herceptin</em>: <em>Kadcyla</em> Carries Torch Across Lines Of HER2 Therapy

Mar 04 2013

Key Cancer Data To Be Unveiled At ESMO In Munich

Oct 10 2018

EU Biosimilar Action: New Competitors For Remicade/Herceptin, Four More Products Await CHMP OK

May 30 2018

Woodcock Hopes I-SPY 2 Trial Is 'Blazing The Trail' For Future Adaptive Design Uptake

Sep 13 2018

Biosimilar Litigation Trends: Settlements, Declaratory Judgment Rejections, Congressional Intervention

Aug 12 2018

Pending Biosimilars

Feb 13 2017

Roche Digs In To Early Breast Cancer With New Perjeta Approvals

Dec 22 2017

Roche's IMpassion130 Is First Positive Phase III Immunotherapy Study In Triple Negative Breast Cancer

Jul 02 2018

New Drugs Shine But Biosimilars Blunt Roche Revenue Rise

Oct 19 2017

Merck's Keytruda Offers Hope And Risk In Early Breast Cancer

Jun 06 2017

Roche’s Master Plan: <em>Perjeta</em> Gains Early Breast Cancer Approval, Late-Stage <em>Kadcyla</em> Data

Sep 30 2013

Roche’s Master Plan: <em>Perjeta</em> Gains Early Breast Cancer Approval, Late-Stage <em>Kadcyla</em> Data

Oct 07 2013

Related Companies

Roche Holding AG

Viatris Inc.

Biocon, Ltd.

Amgen, Inc.

Allergan plc

Teva Pharmaceutical Industries Ltd.

Celltrion, Inc.

Pfizer Inc.

Bristol Myers Squibb Company

Additional Topics

Clinical Trials ImmunoOncology Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window